“For patients in need of cardiovascular or cardiothoracic imaging, the SpotLight Duo is the first cardiothoracic CT incorporating all of Arineta’s patient centric technologies. With one heartbeat, we can provide both high-temporal as well as iso-temporal resolution images that can be used for comprehensive cardiac and thoracic CT assessment,” said Doug Ryan, CEO of Arineta
Building on its ZEISS Medical Ecosystem, several of the new innovations enable seamless data integration and management across the cataract and refractive workflows, creating a new standard for efficient, personalized ophthalmic care.
“For patients in need of cardiovascular or cardiothoracic imaging, the SpotLight Duo is the first cardiothoracic CT incorporating all of Arineta’s patient centric technologies. With one heartbeat, we can provide both high-temporal as well as iso-temporal resolution images that can be used for comprehensive cardiac and thoracic CT assessment,” said Doug Ryan, CEO of Arineta
LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips:
“IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."
Adrian Mendes, Perimeter's Chief Executive Officer, stated, "We believe this additional commercial placement within a major national healthcare system – representing the fifth unit placed with this existing customer network – demonstrates that surgeon end users, as well as other stakeholders within the broader healthcare system, see the value of our technology and are recommending it to their peers. Our aim is to make Perimeter's innovative technology the standard of care in cancer surgery."
Vidhance for Remote Assistance not only improves today’s limitations of head-mounted cameras but also contributes to the transformation of how surgical training is conducted.
Last year, Lunit INSIGHT MMG, Lunit's AI-powered mammography analysis solution, was selected as the preferred AI technology for mammogram screening in the BSNSW State program. The selection of Lunit INSIGHT MMG was a global first, marking the beginning of a new era where national cancer screening organizations assess the operational role of AI solutions in maintaining and improving client outcomes.
"Our partnership with UCB highlights the potential of leveraging AI for improving care for many diseases, including osteoporosis" explains Richard Ljuhar, CEO at ImageBiopsy Lab.
By using this website you agree to accept Medical Device News Magazine Privacy Policy